Tag Archives: mrk

Merck, Endocyte Stop Trial Of Ovarian Cancer Drug

Biotech firm Endocyte (ECYT) and its big-pharma partner Merck (MRK) pulled the plug on their ovarian-cancer treatment Vynfinit Friday, sending both stocks tumbling on the stock market today. The companies said that the Data Safety Monitoring Board’s interim analysis of the phase-three trial of Vynfinit, known generically as vintafolide, was not showing any improvement in patients’ progression-free survival, so it said the trial should be stopped.

HCV Rivalry Heats Up As Merck Combo Shines In Trial

Big pharma Merck reported stellar results for its phase-two hepatitis C (HCV) drug trials Thursday, sparking debate among analysts over its potential to take market share from leader Gilead Sciences. At the International Liver Congress in London, Merck (MRK) reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two potentially combined in one pill

Merck Hepatitis C Combo Scores 98% Cure Rate

Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two combined in one pill taken once per day, the pairing rivals the convenience and effectiveness of